Results 71 to 80 of about 29,549 (204)

A case of ROS1‐rearranged lung adenocarcinoma in a young man with multiple serosal effusions: Diagnostic pitfalls in pericardial fluid cytology

Precision Medical Sciences, EarlyView.
Abstract ROS1‐rearranged lung adenocarcinoma is a rare subset of non‐small‐cell lung cancer, typically occurring in young never‐smokers. Its occurrence in very young men with a fluid‐dominant presentation is unusual and may lead to diagnostic pitfalls.
Thanh Thao Nguyen, Marie Kawakami, Yoshiiku Okanemasa, Yumi Tsubata, Sohsuke Yamada   +4 more
wiley   +1 more source

Targeting ALK, ROS1, and BRAF Kinases [PDF]

Journal of Thoracic Oncology, 2012
Cancer cells demonstrate numerous genetic aberrations. Despite this genetic complexity, it is hypothesized that cancer cells are often addicted to a single oncogenic driver such that inhibition of this single target would lead to cell death.1 Data collected from patients with adenocarcinoma by the Lung Cancer Mutation Consortium (LCMC) demonstrate a ...
Doebele, Robert C., Camidge, D. Ross
openaire   +2 more sources

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok   +5 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma

Therapeutics and Clinical Risk Management, 2020
Shinkichi Takamori, 1 Takashi Seto, 1 Mikako Jinnouchi, 2 Taro Oba, 1 Masafumi Yamaguchi, 1 Mitsuhiro Takenoyama 1 1Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan; 2Department of Radiology,
Takamori S, Seto T, Jinnouchi M, Oba T, Yamaguchi M, Takenoyama M   +5 more
doaj  

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

MET18 Connects the Cytosolic Iron-Sulfur Cluster Assembly Pathway to Active DNA Demethylation in Arabidopsis. [PDF]

PLoS Genetics, 2015
DNA demethylation mediated by the DNA glycosylase ROS1 helps determine genomic DNA methylation patterns and protects active genes from being silenced. However, little is known about the mechanism of regulation of ROS1 enzymatic activity.
Cheng-Guo Duan, Xingang Wang, Kai Tang, Huiming Zhang, Satendra K Mangrauthia, Mingguang Lei, Chuan-Chih Hsu, Yueh-Ju Hou, Chunguo Wang, Yan Li, W Andy Tao, Jian-Kang Zhu   +11 more
doaj   +1 more source

Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI‐52

Cancer Science, EarlyView.
This follow‐up study for TASUKI‐52 trial demonstrates the 4‐year beneficial efficacy of nivolumab (NIV) combined with chemotherapy (CP) and bevacizumab (BEV) in patients with nonsquamous non‐small cell lung cancer (NSCLC) and reveals potential patient backgrounds associated with long‐term survival.
Jong‐Seok Lee, Shunichi Sugawara, Jin‐Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Takako Inoue, Makoto Nishio, Yasushi Goto, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa   +18 more
wiley   +1 more source

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

BMC Cancer, 2019
Background ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC.
Shuguang Xu, Wenxian Wang, Chunwei Xu, Xingliang Li, Junhui Ye, Youcai Zhu, Ting Ge   +6 more
doaj   +1 more source

The role of DNA (de)methylation in immune responsiveness of Arabidopsis. [PDF]

, 2016
DNA methylation is antagonistically controlled by DNA-methyltransferases and DNA-demethylases. The level of DNA methylation controls plant gene expression on a global level. We have examined impacts of global changes in DNA methylation on the Arabidopsis
Ahmad, Alonso, Cao, Carvalho, Chan, Conrath, Conrath, Conrath, Dowen, Durrant, Eden, Ellinger, Frost, Gong, Gong, Jaskiewicz, Jeddeloh, Kanno, Law, Lawton, Le, Lei, Li, Lindroth, Liu, Luna, Luna, Luna, Luna, Luna, López, Matzke, Nuthikattu, Pastor, Pavet, Pavlopoulou, Penterman, Pontier, Pétriacq, Qian, Rasmann, Richards, Ritchie, Saze, Slaughter, Smyth, Stroud, Thomma, Thomma, Thomma, Ton, Ton, Vaillant, Van Wees, Voigt, Vongs, Williams, Worrall, Yu, Zemach, Zheng, Zhong, Zhong, Zhu, Zhu, Zhu   +65 more
core   +1 more source